Insulin glargine
Key facts
| Invented name |
|
| Active substance |
insulin glargine
|
| Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
| Decision number |
P/136/2009
|
| PIP number |
Insulin glargine
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Sanofi-Aventis Deutschland GmbH
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-000396-PIP01-08
|
| Compliance opinion date |
18/11/2011
|
| Compliance outcome |
positive
|